X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ANK-101 is an anchored drug complex composed of interleukin-12 (IL-12) linked to aluminum hydroxide. It is being evaluated for the treatment of solid tumors.
Lead Product(s): ANK-101,Aluminium Hydroxide
Therapeutic Area: Oncology Product Name: ANK-101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
The collaboration aims to evaluate ANK-101, a novel first-in-class anchored IL-12 immunotherapy in combination with Regeneron’s anti-PD-1 therapy, Libtayo (cemiplimab).
Lead Product(s): IL-12 Linked to Aluminum Hydroxide,Cemiplimab
Therapeutic Area: Oncology Product Name: ANK-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 13, 2023
Details:
ANK-101, an interleukin-12 (IL-12) cytokine anchored to aluminum hydroxide, is locally delivered and retained in the tumor microenvironment for several weeks where it mediates recruitment and activation of effector immune cells.
Lead Product(s): ANK-101
Therapeutic Area: Oncology Product Name: ANK-101
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
The collaboration aims to to evaluate ANK-101, a novel first-in-class anchored IL-12 immunotherapy, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab) following the completion of phase I of ANK-101 alone in patients with advanced solid tumors.
Lead Product(s): ANK-101,Pembrolizumab
Therapeutic Area: Oncology Product Name: ANK-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 04, 2023
Details:
The collaboration will focus on the advancement of Ankyra’s lead product candidate, ANK-101, an IL-12-based locally administered immunotherapy, as a potential treatment for lung cancer.
Lead Product(s): ANK-101
Therapeutic Area: Oncology Product Name: ANK-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Lung Cancer Initiative
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 07, 2023
Details:
Under the collaboration with NCI researchers to expand pre-clinical and clinical development of cytokine therapeutic ANK-101 and to combine the expertise to demonstrate the ability of immunotherapy platform to enhance the safety and efficacy of powerful immune agonist drugs.
Lead Product(s): ANK-101
Therapeutic Area: Oncology Product Name: ANK-101
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 18, 2022
Details:
Proceeds from the financing will be used to progress Ankyra’s lead molecule, ANK-101 through Investigational New Drug (IND) enabling studies and into Phase 1 clinical trials, as well as advance additional cytokine programs.
Lead Product(s): ANK-101
Therapeutic Area: Oncology Product Name: ANK-101
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Borealis Ventures
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing November 12, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
